bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Update

bioAffinity Technologies, Inc. (NASDAQ:BIAFGet Free Report) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 46,500 shares, a decrease of 7.7% from the October 15th total of 50,400 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average daily volume of 7,700 shares, the short-interest ratio is presently 6.0 days.

bioAffinity Technologies Stock Down 2.8 %

NASDAQ BIAF opened at $1.39 on Friday. bioAffinity Technologies has a 1-year low of $0.95 and a 1-year high of $3.99. The company has a quick ratio of 11.16, a current ratio of 3.07 and a debt-to-equity ratio of 0.13. The stock’s 50 day moving average is $1.38 and its two-hundred day moving average is $1.66.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BIAF. Citadel Advisors LLC bought a new stake in shares of bioAffinity Technologies during the 3rd quarter worth approximately $60,000. Two Sigma Investments LP bought a new position in shares of bioAffinity Technologies during the first quarter worth approximately $50,000. State Street Corp bought a new stake in bioAffinity Technologies in the 1st quarter valued at $33,000. Finally, Jane Street Group LLC acquired a new position in bioAffinity Technologies in the 3rd quarter valued at $32,000. 1.10% of the stock is owned by institutional investors and hedge funds.

About bioAffinity Technologies

(Get Free Report)

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.

Featured Articles

Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with's FREE daily email newsletter.